Physician profile
Dmitriy Zak
NPI 1548371289
$8,328.34
in general payments reported to CMS, 2019-2025
58 companies · $3,701 in 2025
The $3,701 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,312 · 2020: $315 · 2021: $459 · 2022: $504 · 2023: $646 · 2024: $1,392 · 2025: $3,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,725 · Food and Beverage: $2,612 · Travel and Lodging: $323 · Education: $78.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,725.00 |
| Food and Beverage | $2,612.31 |
| Travel and Lodging | $322.94 |
| Education | $78.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,494.56 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $433.31 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $334.18 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $287.96 | 2019-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $282.52 | 2019-2025 | Darzalex, Carvykti, Akeega |
| Pfizer INC. | $242.78 | 2019-2025 | |
| Lilly USA, LLC | $238.04 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $214.92 | 2021-2025 | Libtayo |
| Eisai INC. | $200.67 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $194.99 | 2019-2025 | |
| Exelixis INC. | $158.26 | 2019-2022 | |
| Amgen INC. | $157.51 | 2019-2023 | Lumakras |
| Rigel Pharmaceuticals, INC. | $156.52 | 2021-2024 | Rezlidhia, Tavalisse |
| Celgene Corporation | $146.54 | 2019-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $132.63 | 2019-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Zak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.